Orexo AB of Sweden has promoted Joseph DeFeo to the job of chief financial officer based in the US. Mr DeFeo joined Orexo in 2013 to run the company’s operations in the US where it generates the majority of its revenue and profits. Orexo’s main therapeutic focus is on treatments for opioid dependence and pain.
Mr DeFeo was previously CFO at Recordati Rare Diseases Inc and before that, director of finance at Archimedes Pharma.
Orexo announced the appointment on 24 October 2018.
Copyright 2018 Evernow Publishing Ltd